Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy
International Journal of Molecular Sciences · 17.08.2026 · 27 (16) · 7356
DOI: 10.3390/ijms27167356 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.08.2026. Verfasst von Katja Seipel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Lymphoma, Large B-Cell, Diffuse, Germ-Line Mutation, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor CAR T-cells are effective immunotherapies for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with overall response rates of 63–84% and complete response rates of 43–54%. Programmed cell death protein 1 (PD-1) is a cell surface receptor with immune check-point function. There are several common germline variants of the PDCD1 gene, including the linked single nucleotide polymorphisms (SNP) rs6710479 and rs2227981. Genetic variants of the immune-checkpoint regulator PDCD1 gene may affect clinical responses to CAR-T cell therapy. In this retrospective single-center study, we assessed the prevalence and outcomes of the PDCD1 gene variants rs6710479 and rs2227981 in r/r DLBCL patients undergoing CAR-T cell therapy. The linked SNP’s were prevalent in 68% of the studied DLBCL patients (CT-AG and TT-AA). In a retrospective comparative analysis, we observed differences in clinical outcomes in PDCD1 CC-GG versus CT-AG and TT-AA carriers with one-year PFS rates of 80% versus 50% and 48% (p = 0.01), and two-year OS rates of 74% versus 55% and 33%, respectively (p = 0.001). In conclusion, common PDCD1 germline variants may have influenced the treatment outcomes in FMC63-anti-CD19 CAR-T cell therapy, and the PDCD1 major allele (CC-GG) may associate with a favorable response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland.
- Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
- Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
ORCID-Profile: Katja Seipel, Seok-Yun Lee, Ulrike Bacher, Thomas Pabst
Zitieren
APA
Seipel, K., Gonçalves Fonseca, M., Shaforostova, I., Lee, S. Y., Bacher, U., & Pabst, T. (2026). Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy. International Journal of Molecular Sciences, 27(16), 7356. https://doi.org/10.3390/ijms27167356
Vancouver
Seipel K, Gonçalves Fonseca M, Shaforostova I, Lee SY, Bacher U, Pabst T. Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy. International Journal of Molecular Sciences. 2026;27(16):7356. doi:10.3390/ijms27167356
BibTeX
@article{Seipel2026,
author = {Seipel, Katja and Gonçalves Fonseca, Marta and Shaforostova, Inna and Lee, Seok-Yun and Bacher, Ulrike and Pabst, Thomas},
title = {Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7356},
doi = {10.3390/ijms27167356}
}
EUVIMED